Fenofibrate is a potent hypolipidemic agent that lowers plasma lipid levels
and may thus decrease the incidence of atherosclerosis. Here we investigat
ed the molecular mechanism of fenofibrate's hypolipidemic action by charact
erizing its in vivo effects on the expression of mRNAs and the activities o
f pivotal enzymes in cholesterol and triglyceride metabolism in the hamster
. Treatment of hamsters with fenofibrate led to a dose-dependent reduction
in serum cholesterol concentrations. Studies on the incorporation of [C-14]
acetate and [C-14]mevalonate into cholesterol suggested that this effect oc
curs primarily through inhibition of cholesterol biosynthesis at steps prio
r to mevalonate. Fenofibrate decreased levels of hepatic enzyme activities
and mRNAs for 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) synthase and
HMG CoA reductase. A potential mechanism for transcriptional regulation of
these enzymes is via SREBP-2 that we found to be suppressed 2-fold by fenof
ibrate. Fenofibrate also lowered circulatory triglyceride levels. In keepin
g with the effect, we observed strong suppression of fatty acid synthase, a
cetyl-CoA carboxylase and apolipoprotein C-III mRNA and stimulation of lipo
protein lipase and acyl-CoA oxidase mRNA in the liver of fenofibrate-treate
d hamsters. These observations suggest that the effect of fenofibrate on tr
iglyceride metabolism is likely to be a result of both decreased fatty acid
synthesis and increased lipoprotein lipase and acyl-CoA oxidase gene expre
ssion in the liver. Surprisingly, alterations in lipoprotein lipase, acyl-C
oA oxidase, acetyl-CoA carboxylase, and apolipoprotein C-III could not be o
bserved in hamster hepatocytes incubated with fenofibric acid in vitro. The
se observations raise the possibility that changes in these genes may be se
condary to the metabolic alterations occurring in animals but not in cultur
ed cells and thus that the effect of fenofibrate on these genes may be indi
rect. (C) 2001 Elsevier Science B.V. All rights reserved.